Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency
Sponsor: Peking University People's Hospital
Summary
To evaluate whether low molecular heparin could improve pregnancy outcomes in pregnancies with protein S deficiency.
Official title: A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Evaluating Whether Low Molecular Heparin Could Improve Pregnancy Outcomes With Protein S Deficiency
Key Details
Gender
FEMALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2024-08-01
Completion Date
2027-12-31
Last Updated
2024-08-01
Healthy Volunteers
No
Conditions
Interventions
Enoxaparin
Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Aspirin
Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Enoxaparin
Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
Locations (1)
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing/Beijing, China